Digoxin
Digoxin, sold as Lanoxin, is a cardiac glycoside, a medicine taken by mouth in the form read here. The US label read, for Lanoxin tablets, lists three uses: mild to moderate heart failure in adults; increasing the strength of the heart muscle contraction in pediatric patients with heart failure; and controlling the ventricular response rate (how fast the lower chambers beat) in adults with chronic atrial fibrillation. For adults with heart failure the label says it improves symptoms, as shown by better exercise capacity and fewer heart-failure hospitalizations and emergency care visits, while having no effect on mortality. Its pediatric use section says safety and effectiveness for heart failure in children have not been established in adequate and well-controlled studies.
Also called Lanoxin
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 3407; UNII 73K4184T59. RxClass lists the FDA established pharmacologic class Cardiac Glycoside; the record is filed under the class page Cardiac glycosides (digoxin) on that evidence. The label read is the Advanz Pharma (US) Corp. label for Lanoxin tablets, application NDA020405, effective 2024-12-05 in openFDA. The Lanoxin injection label (NDA009330) and generic labels were not read. The adult and pediatric statements sit in separate claims and contexts. This page records label indications, the mechanism sentence and the class only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says all of digoxin's actions come from its effect on the sodium-potassium ATPase enzyme, which raises the calcium available inside heart muscle cells.
Claims and evidence
Context Adults with heart failure or chronic atrial fibrillation, as described in the US label of Lanoxin tablets
- Recipient
- Adult
- Population
- Adults with mild to moderate heart failure, and adult patients with chronic atrial fibrillation, as the indications section of the label states.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults, as the label states
- Follow-up
- Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Adults with mild to moderate heart failure
- Adult patients with chronic atrial fibrillation
- Excluded
- None stated
The US label of Lanoxin (digoxin tablets, Advanz Pharma (US) Corp., application NDA020405; the version dated 2024-12-05 in openFDA) describes digoxin as a cardiac glycoside. It lists the treatment of mild to moderate heart failure in adults, and the control of the ventricular response rate in adult patients with chronic atrial fibrillation. For adults with heart failure the label says the medicine improves heart failure symptoms, as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality.
Applies to Adult Adults with heart failure or chronic atrial fibrillation, as described in the US label of Lanoxin tablets
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the label's own statements about exercise capacity and hospitalization are repeated only as the label states them; no trial result is recorded for it in this atlas. The pediatric use is in a separate claim. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (LB-04).
- Retrieved
- Source effective date
- 2024-12-05
- Source state
- Current
- Version fingerprint
9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.1 Heart Failure in Adults
- How it applies
- Label passage quoted in the research quote table (LB-05, LB-10, LB-08).
- Retrieved
- Source effective date
- 2024-12-05
- Source state
- Current
- Version fingerprint
9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.3 Atrial Fibrillation in Adults
- How it applies
- Label passage quoted in the research quote table (LB-06).
- Retrieved
- Source effective date
- 2024-12-05
- Source state
- Current
- Version fingerprint
9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20241205.
- Retrieved
- Source effective date
- 2024-12-05
- Source state
- Current
- Version fingerprint
9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context Children with heart failure, as described in the US label of Lanoxin tablets
- Recipient
- Child
- Population
- Pediatric patients with heart failure, as the indications and pediatric use sections of the label state. The passages read give no age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Pediatric patients, as the label states; no ages given in the passage read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Pediatric patients with heart failure
- Excluded
- None stated
The US label of Lanoxin (digoxin tablets, Advanz Pharma (US) Corp., application NDA020405; the version dated 2024-12-05 in openFDA) says the medicine increases myocardial contractility in pediatric patients with heart failure. Its pediatric use section says the safety and effectiveness of Lanoxin in the treatment of heart failure in children have not been established in adequate and well-controlled studies.
Applies to Child Children with heart failure, as described in the US label of Lanoxin tablets
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says about pediatric patients with heart failure. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label passage read gives no ages. The adult indications are recorded in a separate claim. Of the label's pediatric use section, only the sentence on heart failure in children is recorded; its other statements, and the dosing and safety sections, are not. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].indications_and_usage[0], 1.2 Heart Failure in Pediatric Patients
- How it applies
- Label passage quoted in the research quote table (LB-07).
- Retrieved
- Source effective date
- 2024-12-05
- Source state
- Current
- Version fingerprint
9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].pediatric_use[0], 8.4 Pediatric Use
- How it applies
- The label's pediatric use section says safety and effectiveness for heart failure in children have not been established in adequate and well-controlled studies (LB-11).
- Retrieved
- Source effective date
- 2024-12-05
- Source state
- Current
- Version fingerprint
9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20241205.
- Retrieved
- Source effective date
- 2024-12-05
- Source state
- Current
- Version fingerprint
9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Pregnancy, lactation and children
The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.
In newborns, infants and children 1
The US label of Lanoxin (digoxin tablets, Advanz Pharma (US) Corp., application NDA020405; the version dated 2024-12-05 in openFDA) says the medicine increases myocardial contractility in pediatric patients with heart failure. Its pediatric use section says the safety and effectiveness of Lanoxin in the treatment of heart failure in children have not been established in adequate and well-controlled studies.
Applies to Child Children with heart failure, as described in the US label of Lanoxin tablets
Population, setting and follow-up
- Pediatric patients with heart failure, as the indications and pediatric use sections of the label state. The passages read give no age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Pediatric patients, as the label states; no ages given in the passage read
- Gestational age Not reported
- Postnatal age Not reported
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says about pediatric patients with heart failure. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label passage read gives no ages. The adult indications are recorded in a separate claim. Of the label's pediatric use section, only the sentence on heart failure in children is recorded; its other statements, and the dosing and safety sections, are not. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].indications_and_usage[0], 1.2 Heart Failure in Pediatric Patients
- How it applies
- Label passage quoted in the research quote table (LB-07).
- Retrieved
- Source effective date
- 2024-12-05
- Source state
- Current
- Version fingerprint
9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].pediatric_use[0], 8.4 Pediatric Use
- How it applies
- The label's pediatric use section says safety and effectiveness for heart failure in children have not been established in adequate and well-controlled studies (LB-11).
- Retrieved
- Source effective date
- 2024-12-05
- Source state
- Current
- Version fingerprint
9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20241205.
- Retrieved
- Source effective date
- 2024-12-05
- Source state
- Current
- Version fingerprint
9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists mild to moderate heart failure in adults as an indication: Heart failure
Applies to Adult Adults with heart failure or chronic atrial fibrillation, as described in the US label of Lanoxin tablets
The US label of Lanoxin (digoxin tablets, Advanz Pharma (US) Corp., application NDA020405; the version dated 2024-12-05 in openFDA) describes digoxin as a cardiac glycoside. It lists the treatment of mild to moderate heart failure in adults, and the control of the ventricular response rate in adult patients with chronic atrial fibrillation. For adults with heart failure the label says the medicine improves heart failure symptoms, as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the label's own statements about exercise capacity and hospitalization are repeated only as the label states them; no trial result is recorded for it in this atlas. The pediatric use is in a separate claim. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists control of the ventricular response rate in adults with chronic atrial fibrillation as an indication: Atrial fibrillation (AF)
Applies to Adult Adults with heart failure or chronic atrial fibrillation, as described in the US label of Lanoxin tablets
The US label of Lanoxin (digoxin tablets, Advanz Pharma (US) Corp., application NDA020405; the version dated 2024-12-05 in openFDA) describes digoxin as a cardiac glycoside. It lists the treatment of mild to moderate heart failure in adults, and the control of the ventricular response rate in adult patients with chronic atrial fibrillation. For adults with heart failure the label says the medicine improves heart failure symptoms, as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the label's own statements about exercise capacity and hospitalization are repeated only as the label states them; no trial result is recorded for it in this atlas. The pediatric use is in a separate claim. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Record details
- Record id
cardio:digoxin- Content hash
2c77036e6fc89c1fee24f6afd40546c689ef7aad1873464f7ee79de11fe47834